Thu Sep 19 11:07:00 UTC 2024: ## Coeptis Therapeutics Granted Extension to Regain Nasdaq Listing Compliance

**WEXFORD, PA – September 19, 2024** – Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP), a biopharmaceutical company focused on innovative cell therapies, has been granted an extension by Nasdaq to maintain its listing on the stock market. The company, which had fallen below the minimum bid price requirement, will have until January 15, 2025, to demonstrate compliance.

Coeptis initially received a notice in January 2024 regarding its non-compliance with the minimum bid price requirement. The company has been working to address this issue and presented a plan to the Nasdaq Hearings Panel, including a proposed reverse stock split. The Panel’s decision to grant the extension allows Coeptis to continue its efforts to regain compliance.

“We are pleased with the Nasdaq’s decision to grant us this extension,” stated Dave Mehalick, President and Chief Executive Officer of Coeptis. “This allows us to focus on our mission of developing innovative cell therapies and improving patient outcomes.”

Coeptis is dedicated to developing groundbreaking cell therapies for a variety of diseases, including cancer, autoimmune disorders, and infectious diseases. Its portfolio includes assets licensed from Deverra Therapeutics, the University of Pittsburgh, and VyGen-Bio, showcasing its commitment to pushing the boundaries of cell therapy research.

**About Coeptis Therapeutics Holdings, Inc.**

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. The company is headquartered in Wexford, PA. For more information, visit https://coeptistx.com/.

**Disclaimer:** This press release contains forward-looking statements. These statements involve risks and uncertainties that could cause actual results to differ materially from those anticipated. Investors are cautioned not to place undue reliance on these forward-looking statements.

Read More